Praxis Precision Medicines Inc (PRAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-86.05 Million) by net assets ($1.41 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Praxis Precision Medicines Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Praxis Precision Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PRAX liabilities breakdown for a breakdown of total debt and financial obligations.
Praxis Precision Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Praxis Precision Medicines Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Core & Main Inc
NYSE:CNM
|
0.132x |
|
LandMark Optoelectronics
TWO:3081
|
0.050x |
|
Chifeng Jilong Gold Mining Co Ltd
SHG:600988
|
0.144x |
|
Advanced Fiber Resources Zhuhai Ltd
SHE:300620
|
0.075x |
|
Central Pattana Public Company Limited
BK:CPN
|
0.078x |
|
Central Pattana Public Company Limited
BK:CPN-R
|
0.078x |
|
Texas Pacific Land Trust
NYSE:TPL
|
0.113x |
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
0.041x |
Annual Cash Flow Conversion Efficiency for Praxis Precision Medicines Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Praxis Precision Medicines Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see PRAX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $878.14 Million | $-249.07 Million | -0.284x | +4.11% |
| 2024-12-31 | $445.45 Million | $-131.76 Million | -0.296x | +81.46% |
| 2023-12-31 | $69.67 Million | $-111.14 Million | -1.595x | +34.39% |
| 2022-12-31 | $76.11 Million | $-185.04 Million | -2.431x | -389.60% |
| 2021-12-31 | $250.81 Million | $-124.55 Million | -0.497x | -171.27% |
| 2020-12-31 | $287.46 Million | $-52.62 Million | -0.183x | +77.60% |
| 2019-12-31 | $40.11 Million | $-32.79 Million | -0.817x | +42.09% |
| 2018-12-31 | $14.68 Million | $-20.72 Million | -1.411x | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more